Future opportunities for the diagnosis and treatment of prostate cancer.

about

The development of a web- and a print-based decision aid for prostate cancer screening.Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions

P2860

Q30493869-42E1D928-A468-46A4-9867-A4F427D67664 Q42496163-20EE9D93-EDB2-4F8C-8229-5F72D92B6F6A

P2860

Future opportunities for the diagnosis and treatment of prostate cancer.

Item

http://www.wikidata.org/entity/Q35886572

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Future opportunities for the diagnosis and treatment of prostate cancer.

@ast

Future opportunities for the diagnosis and treatment of prostate cancer.

@en

type

Item

label

Future opportunities for the diagnosis and treatment of prostate cancer.

@ast

Future opportunities for the diagnosis and treatment of prostate cancer.

@en

prefLabel

Future opportunities for the diagnosis and treatment of prostate cancer.

@ast

Future opportunities for the diagnosis and treatment of prostate cancer.

@en

P1476

Future opportunities for the diagnosis and treatment of prostate cancer.

@en

P2093

Schalken JA

http://www.w3.org/2001/XMLSchema#string

Watson RW

http://www.w3.org/2001/XMLSchema#string

P2860

A candidate prostate cancer susceptibility gene at chromosome 17p

The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex

The polycomb group protein EZH2 is involved in progression of prostate cancer

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

EAU guidelines on prostate cancer.

Cadherins and the tumour progression: is it all in a switch?

Cancer risks in BRCA2 mutation carriers.

Cancer Incidence in BRCA1 mutation carriers.

Prostate-specific antigen vaccines for prostate cancer.

P2888

sj.pcan.4500742

P304

S8-S13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.PCAN.4500742

http://www.w3.org/2001/XMLSchema#string

P478

7 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8348299

http://www.w3.org/2001/XMLSchema#string

P6179

1037934240

http://www.w3.org/2001/XMLSchema#string

P698

15365576

http://www.w3.org/2001/XMLSchema#string

Future opportunities for the diagnosis and treatment of prostate cancer.

about

P2860

P2860

Future opportunities for the diagnosis and treatment of prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698